Inactive Instrument

Aimmune Therapeutics, Inc. Stock price

Equities

AIMT

US00900T1079

Biotechnology & Medical Research

Dynamic Chart
Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years CI
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients CI
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology CI
Aimmune Therapeutics, Inc. Presents New PALFORZIA? CI
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis CI
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3 CI
European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for Peanut Allergy in the EU CI
Nestle S A : shrugs off COVID-19 impact thanks to pet food and health nutrition RE
Aimmune Therapeutics, Inc. Announces Executive Changes CI
Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as President CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as CEO CI
GLOBAL MARKETS LIVE: U.S. banks beat expectations Our Logo
Aimmune Therapeutics : Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary DJ
Aimmune Therapeutics : shareholders accept $2 billion Nestle tender offer RE
More news
Managers TitleAgeSince
Compliance Officer 57 20-09-30
General Counsel - -
Corporate Officer/Principal - -
More insiders
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.
More about the company
  1. Stock
  2. Equities
  3. Stock Aimmune Therapeutics, Inc. - Nasdaq